WCM Global Growth Limited Reports October 2026 Monthly NTA and Portfolio Return of -6.27%

Aakashdeep

12 November 2026 03:47 PM AEDT

WCM Global Growth Limited Reports October 2026 Monthly NTA and Portfolio Return of -6.27%

Image Source: Krish Capital Pty Ltd

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

WCM Global Growth Limited (ASX:WQG) has disclosed its portfolio update for the month ended 31 October 2026, reporting a portfolio return of -6.27% against a benchmark return of -2.80% for the MSCI All Country World Index (ex-Australia), with NTA before tax of A$1.930 per share based on issued capital of 279,877,141 shares.

Key Points

Portfolio return of -6.27% for October 2026, compared with the benchmark return of -2.80%
NTA before tax of A$1.930, NTA after tax and before tax on unrealised gains of A$1.845, and NTA after tax of A$1.769 per share
Month-end closing share price of A$2.080, with a fully franked annual dividend of A8.81 cents
Taiwan Semiconductor was the largest portfolio holding at 6.14%, followed by Microsoft Corporation at 4.79% and Siemens Energy at 4.44%
US-based IQVIA disclosed as a recent addition to the portfolio's overweight Health Care allocation

October 2026 Portfolio Performance and Benchmark Comparison

According to the filing, the portfolio delivered a return of -6.27% during October 2026, while the benchmark returned -2.80%, resulting in value added of -3.47% for the month. Over three years, the portfolio returned 21.12% annualised against a benchmark of 18.74%, and since the company's inception on 21 June 2017, the portfolio has returned 14.78% annualised compared with the benchmark's 13.08%. Stock selection was identified as the major driver of underperformance in the month, with selection strongest in Materials, Financials and Real Estate, while holdings in Information Technology, Industrials and Health Care detracted.

Top 10 Holdings and Portfolio Construction as at 31 October 2026

The filing disclosed that the portfolio held between 20 and 40 stocks as at 31 October 2026. Taiwan Semiconductor was the largest holding at 6.14%, followed by Microsoft Corporation at 4.79%, Siemens Energy at 4.44%, Meta Platforms at 3.87%, Rolls-Royce Holdings at 3.87%, Amazon.com at 3.53%, SharkNinja at 3.33%, Saab at 3.30%, Seagate Technology Holdings at 3.11%, and BAE Systems at 2.73%. The portfolio focuses primarily on the Consumer, Technology and Health Care sectors, with a typical cash allocation of between 0% and 7%. Fees include a management fee of 1.25% per annum and an administration fee of 0.10% per annum.

Addition of IQVIA to Health Care Allocation

The filing stated that a recent addition to the portfolio's overweight Health Care allocation is US-based IQVIA. The filing described IQVIA as one of the world's largest operators of clinical trials for pharmaceutical and biotech companies, also operating a health data and analytics business. The filing noted that drug developers are increasingly outsourcing trials and concentrating this work with fewer, larger partners, and that IQVIA is winning a growing share of that work, particularly among smaller drug developers. The filing identified IQVIA's proprietary data, global scale in running trials and its role as an adviser on trial design as factors noted by portfolio managers.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.